A review of computational drug repurposing

Although sciences and technology have progressed rapidly, de novo drug development has been a costly and time-consuming process over the past decades. In view of these circumstances, 'drug repurposing' (or 'drug repositioning') has appeared as an alternative tool to accelerate dr...

Full description

Saved in:
Bibliographic Details
Published inTranslational and clinical pharmacology Vol. 27; no. 2; pp. 59 - 63
Main Author Park, Kyungsoo
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society for Clinical Pharmacology and Therapeutics 01.06.2019
대한임상약리학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Although sciences and technology have progressed rapidly, de novo drug development has been a costly and time-consuming process over the past decades. In view of these circumstances, 'drug repurposing' (or 'drug repositioning') has appeared as an alternative tool to accelerate drug development process by seeking new indications for already approved drugs rather than discovering de novo drug compounds, nowadays accounting for 30% of newly marked drugs in the U.S. In the meantime, the explosive and large-scale growth of molecular, genomic and phenotypic data of pharmacological compounds is enabling the development of new area of drug repurposing called computational drug repurposing. This review provides an overview of recent progress in the area of computational drug repurposing. First, it summarizes available repositioning strategies, followed by computational methods commonly used. Then, it describes validation techniques for repurposing studies. Finally, it concludes by discussing the remaining challenges in computational repurposing.
ISSN:2289-0882
2383-5427
DOI:10.12793/tcp.2019.27.2.59